drug1	drug2	Label	description
DB04571	DB00460	1	The therapeutic efficacy of Acetohexamide can be increased when used in combination with Trioxsalen.
DB00855	DB00460	1	The risk or severity of methemoglobinemia can be increased when Aminolevulinic acid is combined with Ambroxol.
DB08897	DB00424	2	1,10-Phenanthroline may increase the neuromuscular blocking activities of Aclidinium.
DB00670	DB06148	2	The therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.
DB09275	DB00635	3	Acepromazine may increase the neurotoxic activities of Bismuth subcitrate potassium.
DB03754	DB00860	3	The serum concentration of Flecainide can be increased when it is combined with Tromethamine.
DB00615	DB01435	4	The metabolism of (R)-warfarin can be increased when combined with Rifabutin.
DB00252	DB00199	4	The serum concentration of Phenytoin can be decreased when it is combined with (6R)-Folinic acid.
DB00590	DB06262	5	The metabolism of (R)-warfarin can be decreased when combined with Doxazosin.
DB00421	DB00751	5	1-benzylimidazole may decrease the antihypertensive activities of Spironolactone.
DB06605	DB00686	6	(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Apixaban.
DB00682	DB01118	6	(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Warfarin.
DB00958	DB00445	7	The risk or severity of bleeding can be increased when (R)-warfarin is combined with Carboplatin.
DB00903	DB00695	7	The protein binding of (R)-warfarin can be decreased when combined with Etacrynic acid.
DB00230	DB01106	8	The therapeutic efficacy of 1,2-Benzodiazepine can be increased when used in combination with Pregabalin.
DB01037	DB00295	8	The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with (R)-warfarin.
DB00672	DB01297	9	Chlorpropamide may increase the anticoagulant activities of (R)-warfarin.
DB08907	DB01059	9	Canagliflozin may increase the hypoglycemic activities of 2,4-thiazolidinedione.
DB00862	DB01119	10	The metabolism of (R)-warfarin can be decreased when combined with Vardenafil.
DB00203	DB09070	10	The risk or severity of hemorrhage can be increased when (R)-warfarin is combined with Sildenafil.
DB13179	DB09274	11	The metabolism of (R)-warfarin can be decreased when combined with Troleandomycin.
DB00196	DB00758	11	The serum concentration of (R)-warfarin can be increased when it is combined with Fluconazole.
DB00498	DB00550	12	(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Phenindione.
DB12598	DB04573	12	(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Nafamostat.
DB02513	DB00396	13	The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Thymol.
DB01141	DB00396	13	The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Micafungin.
DB00866	DB00221	14	The risk or severity of adverse effects can be increased when Alprenolol is combined with (R)-warfarin.
DB00612	DB05039	14	1-benzylimidazole may decrease the antihypertensive activities of Bisoprolol.
DB00531	DB06176	15	The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Cyclophosphamide.
DB00531	DB06704	15	The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Cyclophosphamide.
DB00611	DB00366	16	The risk or severity of adverse effects can be increased when Butorphanol is combined with 1,2-Benzodiazepine.
DB00807	DB06204	16	The risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Proparacaine.
DB00903	DB00728	17	The protein binding of (R)-warfarin can be decreased when combined with Etacrynic acid.
DB00695	DB00565	17	1-benzylimidazole may decrease the antihypertensive activities of Furosemide.
DB01390	DB06701	18	The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be increased when it is combined with Sodium bicarbonate.
DB00927	DB00422	18	The metabolism of (R)-warfarin can be decreased when combined with Famotidine.
DB00248	DB01193	19	The serum concentration of (R)-warfarin can be increased when it is combined with Cabergoline.
DB00589	DB00696	19	The risk or severity of adverse effects can be increased when Lisuride is combined with (R)-warfarin.
DB01624	DB06825	20	The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with (R)-warfarin.
DB00333	DB09080	20	The serum concentration of (R)-warfarin can be increased when it is combined with Methadone.
DB00732	DB01627	21	The therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.
DB00483	DB00618	21	The therapeutic efficacy of Gallamine triethiodide can be decreased when used in combination with 1,10-Phenanthroline.
DB08906	DB00732	22	Fluticasone furoate may increase the anticoagulant activities of (R)-warfarin.
DB01708	DB01226	22	The serum concentration of (1,2,6,7-3H)Testosterone can be increased when it is combined with Prasterone.
DB00937	DB00543	23	The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Diethylpropion.
DB00191	DB00458	23	The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
DB00399	DB00997	24	The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Zoledronic acid.
DB00884	DB06263	24	The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Risedronic acid.
DB06707	DB00571	25	1-benzylimidazole may decrease the hypertensive activities of Levonordefrin.
DB00714	DB00373	25	The metabolism of (R)-warfarin can be decreased when combined with Apomorphine.
DB01045	DB06209	26	The metabolism of (R)-warfarin can be increased when combined with Rifampicin.
DB00338	DB00758	26	The metabolism of (R)-warfarin can be decreased when combined with Omeprazole.
DB08981	DB04576	27	The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with (R)-warfarin.
DB00939	DB00817	27	The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with (R)-warfarin.
DB00932	DB04573	28	The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with (R)-warfarin.
DB00619	DB00448	28	Imatinib may increase the anticoagulant activities of (R)-warfarin.
DB01024	DB00695	29	The risk or severity of bleeding can be increased when Mycophenolic acid is combined with (R)-warfarin.
DB01283	DB00887	29	The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with (R)-warfarin.
DB01297	DB00457	30	The metabolism of Practolol can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB01351	DB00999	30	The metabolism of (R)-warfarin can be increased when combined with Amobarbital.
DB00968	DB09241	31	1-benzylimidazole may decrease the antihypertensive activities of Methyldopa.
DB00968	DB09245	31	1-benzylimidazole may decrease the antihypertensive activities of Methyldopa.
DB00313	DB00268	32	The serum concentration of (6R)-Folinic acid can be decreased when it is combined with Valproic acid.
DB00181	DB00765	32	Baclofen may increase the central nervous system depressant (CNS depressant) activities of 1,2-Benzodiazepine.
DB00539	DB00604	33	The risk or severity of bleeding can be increased when Toremifene is combined with (R)-warfarin.
DB00280	DB09039	33	The metabolism of (R)-warfarin can be decreased when combined with Disopyramide.
DB01280	DB08868	34	The risk or severity of bleeding can be increased when (R)-warfarin is combined with Nelarabine.
DB01656	DB08877	34	The metabolism of (R)-warfarin can be decreased when combined with Roflumilast.
DB01356	DB00875	35	The risk or severity of adverse effects can be increased when Lithium cation is combined with (R)-warfarin.
DB00444	DB00541	35	The serum concentration of (R)-warfarin can be increased when it is combined with Teniposide.
DB06288	DB00679	36	The risk or severity of adverse effects can be increased when Amisulpride is combined with (R)-warfarin.
DB00391	DB06144	36	The risk or severity of adverse effects can be increased when Sulpiride is combined with (R)-warfarin.
DB00368	DB00370	37	1-benzylimidazole may decrease the hypertensive activities of Norepinephrine.
DB00852	DB09167	37	The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Pseudoephedrine.
DB00883	DB00898	38	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Isosorbide dinitrate.
DB00727	DB06237	38	1-benzylimidazole may decrease the antihypertensive activities of Nitroglycerin.
DB09300	DB09290	39	The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with 1,10-Phenanthroline.
DB00899	DB09272	39	The risk or severity of hypertension can be increased when Remifentanil is combined with 1-benzylimidazole.
DB11156	DB03615	40	The risk or severity of CNS depression can be increased when Pyrantel is combined with 1,2-Benzodiazepine.
DB01336	DB06696	40	The therapeutic efficacy of Metocurine can be decreased when used in combination with 1,10-Phenanthroline.
DB09241	DB00454	41	The serum concentration of (R)-warfarin can be increased when it is combined with Methylene blue.
DB01037	DB00454	41	The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with (R)-warfarin.
DB00421	DB00091	42	1-benzylimidazole may decrease the antihypertensive activities of Spironolactone.
DB00384	DB00864	42	The metabolism of (R)-warfarin can be decreased when combined with Triamterene.
DB01289	DB01032	43	Glisoxepide may increase the anticoagulant activities of (R)-warfarin.
DB00252	DB01327	43	The serum concentration of Phenytoin can be decreased when it is combined with (6R)-Folinic acid.
DB09245	DB00289	44	The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with (R)-warfarin.
DB01367	DB00289	44	The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with (R)-warfarin.
DB08824	DB00215	45	2,5-Dimethoxy-4-ethylamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
DB08824	DB01175	45	2,5-Dimethoxy-4-ethylamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
DB01359	DB06709	46	The risk or severity of adverse effects can be increased when Penbutolol is combined with (R)-warfarin.
DB00373	DB06709	46	The metabolism of (R)-warfarin can be decreased when combined with Timolol.
DB00518	DB12332	47	The metabolism of (R)-warfarin can be increased when combined with Albendazole.
DB01591	DB01243	47	The metabolism of Solifenacin can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB01076	DB09055	48	The risk or severity of bleeding can be increased when Atorvastatin is combined with (R)-warfarin.
DB01394	DB01039	48	The metabolism of Colchicine can be decreased when combined with 6-Deoxyerythronolide B.
DB00844	DB00999	49	The risk or severity of adverse effects can be increased when Nalbuphine is combined with 1,2-Benzodiazepine.
DB00176	DB01063	49	The serum concentration of (R)-warfarin can be increased when it is combined with Fluvoxamine.
DB04878	DB00230	50	The risk or severity of hypoglycemia can be increased when Voglibose is combined with 2,4-thiazolidinedione.
DB01124	DB00230	50	The metabolism of (R)-warfarin can be decreased when combined with Tolbutamide.
DB01070	DB01021	51	The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with 1alpha-Hydroxyvitamin D5.
DB06410	DB00232	51	The risk or severity of adverse effects can be increased when Doxercalciferol is combined with 1alpha-Hydroxyvitamin D5.
DB06204	DB00377	52	The risk or severity of adverse effects can be increased when Tapentadol is combined with (R)-warfarin.
DB00193	DB00904	52	The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Tramadol.
DB08439	DB01104	53	The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with (R)-warfarin.
DB00945	DB06700	53	Acetylsalicylic acid may increase the anticoagulant activities of (R)-warfarin.
DB00390	DB00989	54	The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Digoxin.
DB01203	DB08865	54	The metabolism of Nadolol can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB00310	DB00215	55	1-benzylimidazole may decrease the antihypertensive activities of Chlorthalidone.
DB00232	DB00472	55	The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Methyclothiazide.
DB00796	DB01412	56	The metabolism of (R)-warfarin can be decreased when combined with Candesartan cilexetil.
DB00796	DB00742	56	The metabolism of (R)-warfarin can be decreased when combined with Candesartan cilexetil.
DB00452	DB00529	57	The risk or severity of bleeding can be increased when Framycetin is combined with (R)-warfarin.
DB00864	DB00573	57	The serum concentration of (R)-warfarin can be increased when it is combined with Tacrolimus.
DB00290	DB01092	58	The risk or severity of adverse effects can be increased when Bleomycin is combined with 2-Methoxyethanol.
DB00544	DB00511	58	The risk or severity of adverse effects can be increased when (6R)-Folinic acid is combined with Fluorouracil.
DB00332	DB00761	59	The therapeutic efficacy of Ipratropium can be decreased when used in combination with 1,10-Phenanthroline.
DB00657	DB00761	59	1-benzylimidazole may decrease the antihypertensive activities of Mecamylamine.
DB01168	DB00492	60	The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with (R)-warfarin.
DB00752	DB01359	60	The serum concentration of (R)-warfarin can be increased when it is combined with Tranylcypromine.
DB00191	DB09128	61	The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
DB09352	DB00831	61	The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine.
DB00727	DB01200	62	1-benzylimidazole may decrease the antihypertensive activities of Nitroglycerin.
DB00727	DB00589	62	1-benzylimidazole may decrease the antihypertensive activities of Nitroglycerin.
DB01033	DB00993	63	The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Mercaptopurine.
DB06772	DB00515	63	The metabolism of (R)-warfarin can be decreased when combined with Cabazitaxel.
DB01104	DB09042	64	The risk or severity of bleeding can be increased when Sertraline is combined with (R)-warfarin.
DB09241	DB09244	64	The serum concentration of (R)-warfarin can be increased when it is combined with Methylene blue.
DB01192	DB06767	65	The metabolism of Oxymorphone can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB01356	DB01390	65	The risk or severity of adverse effects can be increased when Lithium cation is combined with (R)-warfarin.
DB12364	DB13167	66	(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Betrixaban.
DB06605	DB13783	66	(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Apixaban.
DB00827	DB11126	67	The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Cinoxacin.
DB00240	DB00375	67	The risk or severity of hyperglycemia can be increased when Alclometasone is combined with 2,4-thiazolidinedione.
DB00584	DB00700	68	1-benzylimidazole may decrease the antihypertensive activities of Enalapril.
DB01395	DB12598	68	The risk or severity of adverse effects can be increased when Drospirenone is combined with (R)-warfarin.
DB01227	DB01365	69	The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with 1,10-Phenanthroline.
DB01192	DB01576	69	The metabolism of Oxymorphone can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB06730	DB04272	70	The risk or severity of adverse effects can be increased when Gestodene is combined with (R)-warfarin.
DB00256	DB09268	70	Lymecycline may increase the anticoagulant activities of (R)-warfarin.
DB01577	DB00780	71	The metabolism of Metamfetamine can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB01274	DB00248	71	The metabolism of (R)-warfarin can be decreased when combined with Arformoterol.
DB00684	DB01009	72	The risk or severity of bleeding can be increased when Tobramycin is combined with (R)-warfarin.
DB03615	DB00991	72	The risk or severity of bleeding can be increased when Ribostamycin is combined with (R)-warfarin.
DB00617	DB09280	73	The metabolism of (R)-warfarin can be decreased when combined with Paramethadione.
DB00227	DB00763	73	The risk or severity of bleeding can be increased when Lovastatin is combined with (R)-warfarin.
DB11921	DB01420	74	Deflazacort may increase the anticoagulant activities of (R)-warfarin.
DB01260	DB08804	74	The risk or severity of hyperglycemia can be increased when Desonide is combined with 2,4-thiazolidinedione.
DB00615	DB00860	75	The metabolism of (R)-warfarin can be increased when combined with Rifabutin.
DB00252	DB08875	75	The serum concentration of Phenytoin can be decreased when it is combined with (6R)-Folinic acid.
DB09352	DB00835	76	The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with 3-isobutyl-1-methyl-7H-xanthine.
DB00937	DB00370	76	The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Diethylpropion.
DB01200	DB06695	77	The serum concentration of (R)-warfarin can be increased when it is combined with Bromocriptine.
DB06800	DB06702	77	Abacavir may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB09063	DB09095	78	The serum concentration of (R)-warfarin can be increased when it is combined with Ceritinib.
DB09063	DB09091	78	The serum concentration of (R)-warfarin can be increased when it is combined with Ceritinib.
DB09244	DB00708	79	The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with (R)-warfarin.
DB01247	DB00802	79	The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with (R)-warfarin.
DB00619	DB09288	80	Imatinib may increase the anticoagulant activities of (R)-warfarin.
DB00908	DB01174	80	The serum concentration of (R)-warfarin can be increased when it is combined with Quinidine.
DB00302	DB00890	81	Tranexamic acid may increase the thrombogenic activities of Albutrepenonacog alfa.
DB00480	DB01234	81	The risk or severity of bleeding can be increased when (R)-warfarin is combined with Lenalidomide.
DB01071	DB06216	82	The serum concentration of (R)-warfarin can be increased when it is combined with Mequitazine.
DB01078	DB13231	82	The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Deslanoside.
DB13139	DB00774	83	The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Levosalbutamol.
DB01260	DB00903	83	The risk or severity of hyperglycemia can be increased when Desonide is combined with 2,4-thiazolidinedione.
DB00370	DB00388	84	Mirtazapine may increase the anticoagulant activities of (R)-warfarin.
DB00543	DB00723	84	The risk or severity of bleeding can be increased when Amoxapine is combined with (R)-warfarin.
DB04896	DB00964	85	The serum concentration of (R)-warfarin can be increased when it is combined with Milnacipran.
DB06700	DB00841	85	The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with (R)-warfarin.
DB00437	DB00722	86	The risk or severity of bleeding can be increased when Allopurinol is combined with (R)-warfarin.
DB00437	DB00232	86	The risk or severity of bleeding can be increased when Allopurinol is combined with (R)-warfarin.
